Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open‐label feasibility trial-Reference-Cited by-同舟云学术

Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open‐label feasibility trial

Published:2021-11-28 Issue: Volume: Page:
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Goebeler M.¹,Bata‐Csörgő Z.²,De Simone C.³,Didona B.⁴,Remenyik E.⁵,Reznichenko N.⁶,Stoevesandt J.¹,Ward E.S.⁷,Parys W.⁸,Haard H.⁸,Dupuy P.⁸,Verheesen P.⁸,Schmidt E.⁹,Joly P.¹⁰,

Affiliation:

1. Department of Dermatology, Venereology and Allergology University Hospital Würzburg Würzburg Germany

2. Department of Dermatology and Allergology University of Szeged Szeged Hungary

3. Department of Dermatology Catholic University of the Sacred Heart Policlinic A. Gemelli Rome Italy

4. Dermatopathic Institute of the Immaculate Rome Italy

5. Department of Dermatology Faculty of Medicine University of Debrecen Debrecen Hungary

6. Zaporizhzhya State Medical University Zaporizhzhya Ukraine

7. Centre for Cancer Immunology University of Southampton Southampton UK

8. argenx Ghent Belgium

9. Department of Dermatology University of Lübeck Lübeck Germany

10. Department of Dermatology Rouen University Hospital Rouen France

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.20782

Reference35 articles.

1. Epidemiology of Pemphigus

2. Pemphigus

3. Pemphigus, Bullous Impetigo, and the Staphylococcal Scalded-Skin Syndrome

4. Incidence and Mortality of Pemphigus in France

5. Pemphigus

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of immunoglobulin transport receptor, neonatal Fc receptor in mucosal infection and immunity and therapeutic intervention;International Immunopharmacology;2024-09

2. Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+);Neurotherapeutics;2024-09

3. Updates on the Management of Autoimmune Bullous Diseases;Indian Dermatology Online Journal;2024-08-30

4. 2025 update on clinical trials in immune thrombocytopenia;American Journal of Hematology;2024-08-06

5. Efgartigimod-associated Kaposi’s varicelliform eruption and herpetic conjunctivitis in a patient with seropositive ocular myasthenia gravis: a case report and review;Frontiers in Immunology;2024-08-01